**A Breakthrough in Alzheimer’s Detection: Blood Test Predicts Disease Years Before Symptoms**
A blood examination that can identify Alzheimer’s disease 5-10 years prior to the manifestation of memory issues is transitioning from research into clinical application. At the Alzheimer’s Association International Conference, scientists presented panels of plasma biomarkers with notable predictive precision for cognitive decline, particularly a phosphorylated variant of the tau protein, pTau217.
In the past, Alzheimer’s was diagnosed only after cognitive symptoms appeared. This novel method permits earlier identification, potentially altering the diagnostic criteria for the disease. The tau protein, crucial for neuronal stability, experiences changes such as phosphorylation that impede its functionality, culminating in neurofibrillary tangles typical of Alzheimer’s.
Significant studies emphasized at the conference include one from Mass General Brigham, where increased levels of pTau217 forecasted cognitive decline more accurately than amyloid PET imaging. A research published in *The Lancet* involving older adults demonstrated that pTau217 could indicate Alzheimer’s years ahead of symptoms, particularly in individuals with genetic predispositions like the APOE ε4 allele.
Nonetheless, early identification poses challenges. While advancements in blood testing for Alzheimer’s are progressing, the efficacy of early treatment remains ambiguous. Existing disease-modifying therapies such as lecanemab and donanemab yield better results when initiated early. Hence, recognizing candidates promptly through blood tests might expand therapeutic opportunities.
The primary short-term value of the test lies in enhancing clinical trials by pinpointing participants more likely to benefit from treatments aimed at amyloid or tau. For the moment, the amalgamation of blood tests, imaging, and cognitive evaluations presents a thorough strategy for Alzheimer’s diagnostics, as the discipline continues to advance with fresh research developments.